Skip to main content

Financial News

  • Diplomat’s profit, margin feel impact of DIR fees in Q3

    FLINT, Mich. — Diplomat Pharmacy on Wednesday shared the financial results for its third quarter ended Sept. 30, showing increases in revenue and dispensed prescriptions, but alongside a drop in profit per prescription dispensed and its gross margin. 
     
  • AmerisourceBergen reports Q4, FY16 results

    VALLEY FORGE, Pa. — AmerisourceBergen on Wednesday reported its results from the fourth quarter, ended Sept. 30, and its fiscal year. The company posted a 5.9% revenue increase for the quarter, bringing in $37.6 billion, and saw a fiscal year revenue increase of 8%, bringing in $146.8 billion. 
     
  • Kohlberg Kravis Roberts & Co. to sell remaining stake in Walgreens Boots Alliance

    DEERFIELD, Ill. – Walgreens Boots Alliance on Tuesday announced that affiliates of Kohlberg Kravis Roberts & Co. intend to offer approximately 20.5 million shares of the company's common stock for sale in an underwritten secondary offering pursuant to the shelf registration statement filed with the Securities and Exchange Commission on Feb. 17, 2016.
     

  • An expanding Weis Markets records Q3 revenue growth of 4.4%

    SUNBURY, Pa. - Weis Markets on Monday posted a third quarter sales increase of 4.4% to $743 million compared the same period in 2015. Comparable store sales for the 13-week period ended Sept. 24, 2016 increased 2.7%.

    In the third quarter, the company's net income declined 16.9% to $10.6 million compared to $12.8 million for the same period in 2015. The company's earnings per share totaled $0.40 compared to $0.48 per share for the same period in 2015.

  • Cardinal Health realizes revenue gains but earnings decline behind pricing headwinds

    DUBLIN, Ohio - Cardinal Health on Monday reported first-quarter fiscal year 2017 revenue of $32 billion, an increase of 14% from the comparable quarter last year.

    The company also reported a decline in GAAP operating earnings of 14% to $535 million. GAAP diluted earnings per share decreased 17% to $0.96.

  • McKesson recasts fiscal outlook to reflect lower pharma pricing

    SAN FRANCISCO – McKesson on Thursday reported that revenues for the second quarter ended Sept. 30, 2016, totaled $50 billion, up 2% compared to the year-ago period. On the basis of U.S. generally accepted accounting principles, second-quarter earnings per diluted share from continuing operations was $1.35, compared to $2.65 a year ago.

    The company is updating its outlook from the previous range of $13.43 to $13.93 per diluted share to a new range of $12.35 to $12.85 per diluted share for the fiscal year ending March 31, 2017.

X
This ad will auto-close in 10 seconds